0RD1.LSE

Camurus AB

0RD1.LSE, UK

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

https://www.camurus.com

Stock Price

SEK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.91

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

22.91 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.12

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Camurus AB

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

3.28

Latest Release

Date

2025-09-30

EPS Actual

3.1943

EPS Estimate

3.81

EPS Difference

-0.6157

Surprise Percent

-16.1601%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8)
Defensive
Highly Defensive(8)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9.5)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(8)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

SEK 0

Cost Of Revenue

SEK 0

Gross Profit

SEK 0

Operating Expenses

SEK 0

Operating Income

SEK 0

Interest Expense

SEK 0

Pretax Income

SEK 0

Net Income

SEK 0

Income Tax Expense

SEK 0

EBITDA

SEK 0

Total Other Income Expense Net

SEK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

SEK 0

Short Term Investments

SEK 0

Receivables

SEK 0

Inventories

SEK 0

Total Current Assets

SEK 0

Property Plant Equipment

SEK 0

Total Assets

SEK 0

Payables

SEK 0

Short Term Debt

SEK 0

Long Term Debt

SEK 0

Total Liabilities

SEK 0

Equity

SEK 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

SEK 0

Depreciation

SEK 0

Change In Working Capital

SEK 0

Cash From Operations

SEK 0

Capital Expenditures

SEK 0

Cash From Investing

SEK 0

Cash From Financing

SEK 0

Net Change In Cash

SEK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.